UNSPSC 51292026: Melitracen hydrochloride

This classification denotes an antidepressant agent with the molecular formula C21H25N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J3448GKP5W, chemically known as 9-(3-dimethylaminopropylidene)-10,10-dimethyl-9,10-dihydroanthracene hydrochloride but more generally known as melitracen hydrochloride, which bears US NIH Compound Identifier 25381. European Medicines Agency schedules Melitracen hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03134MIG.

UNSPSC 51292026 Melitracen hydrochloride is a Commodity code nominally identifying a single pharmaceutical product, but recent state and local opportunities tagged under this code show little activity directly matching the specific drug name. The most concrete recent solicitation—Seminole County, Florida's IFB60459723LAS posted June 30, 2026—seeks procurement of naloxone and drug deactivation systems for community health initiatives, not melitracen. The Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) is exploratory market intelligence on direct-to-manufacturer pharmacy programs, and Minnesota's MMCAP RFP S1070000015802 (posted January 20, 2026) covers generic multi-source pharmaceuticals and OTC products through authorized wholesalers, neither of which target melitracen specifically. The code shows activity among state health departments and regional cooperative purchasing entities, but the mismatch between the code's nominal scope and what is actually being procured suggests either miscoding in recent opportunities or minimal current demand for melitracen itself under this taxonomy.

Geographic activity spans Florida, Texas, and Minnesota based on recent postings. Issuing bodies include county health departments (Seminole County), state health agencies (Texas HHS, Minnesota Department of Administration), and multistate cooperative purchasing alliances (MMCAP). The Seminole County opportunity, an IFB with a response deadline of July 26, 2023, remains the most concrete pharmaceutical procurement on record, though its focus on naloxone rather than melitracen underscores the alignment gap. Without additional recent solicitations explicitly naming melitracen or melitracen-containing formulations, the code appears quiet for purposes of state and local business development targeting this specific pharmaceutical.